Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PVLA
- Price
- 22.05
- Stock movement up
- +0.87 (1.72%)
- Company name
- Palvella Therapeutics, Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 575.76M
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 203.97%
- 3 year return
- -27.17%
- 5 year return
- -26.79%
- 10 year return
- -15.03%
Last updated: 2025-09-15
Palvella’s QTORIN rapamycin is its main value driver. Read why PVLA could pay off for patient long-term investors betting on its promising pipeline.
September 22, 2025
iO Charts is a Seeking Alpha partner
Palvella Therapeutics (PVLA) Monday said that it has been added to the broad-market Russell 3000 Index and the Russell 2000 Index, effective after the U.S. market opens on June 30, as part of the 202...
June 30, 2025
iO Charts is a Seeking Alpha partner
DIVIDENDS
PVLA does not pay dividends or no data was received
Palvella Therapeutics (PVLA) reports Q1 GAAP EPS of -$0.74. With $75.6M in cash reserves, operations are funded through H2 2027.
May 15, 2025
iO Charts is a Seeking Alpha partner
Discover Palvella Therapeutics' FY financial results with a GAAP EPS of -$7.83. Uncover insights into their progress and performance challenges.
March 31, 2025
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
Learn about Palvella Therapeutics (PVLA) filing a prospectus for the resale of 5.6M common shares and what it means for potential investors.
December 31, 2024
iO Charts is a Seeking Alpha partner
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 49.88 |
| Daily high | 52.87 |
| Daily low | 48.65 |
| Daily Volume | 132K |
| All-time high | 756.00 |
| 1y analyst estimate | 37.33 |
| Beta | - |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| PVLA | S&P500 | |
| Current price drop from All-time high | -93.21% | -1.46% |
| Highest price drop | -99.14% | -56.47% |
| Date of highest drop | 11 Jul 2024 | 9 Mar 2009 |
| Avg drop from high | -62.77% | -10.99% |
| Avg time to new high | 36 days | 12 days |
| Max time to new high | 1891 days | 1805 days |
COMPANY DETAILS
Marketcap
575.76M
Marketcap category
Small-cap
Description
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
Employees
14
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner